-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Protagenic Therapeutics (OTCMKTS:PTIX) Share Price Passes Below 200-Day Moving Average of $0.76
Protagenic Therapeutics (OTCMKTS:PTIX) Share Price Passes Below 200-Day Moving Average of $0.76
Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.
Protagenic Therapeutics Price Performance
The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.
Get Protagenic Therapeutics alerts:Institutional Trading of Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.
Protagenic Therapeutics Company Profile
(Get Rating)Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.
在週二的交易中,Protag Treateutics,Inc.(OTCMKTS:PTIX-GET評級)的股價跌破了200日移動平均線。該股的200日移動均線為0.76美元,最低交易價格為0.67美元。Protag Treateutics的股票最後交易價格為0.68美元,成交量為18,049股。
Protagenic Therapeutics Price Performance
他汀類治療藥物的價格表現
The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.
該業務的50日移動均線價格為0.66美元,其200日移動均線價格為0.76美元。該公司的負債權益比率為0.04,速動比率為19.47,流動比率為19.47。
Institutional Trading of Protagenic Therapeutics
前列腺素治療藥物的制度性交易
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.
一家機構投資者最近提高了其在普羅吉治療公司股票的頭寸。根據復興科技有限公司在最近向美國證券交易委員會(美國證券交易委員會)披露的信息,該公司在第一季度將其在普羅吉治療公司(場外交易代碼:PTIX-GET評級)的股份增加了69.2%。該基金在此期間額外購買了41,800股後,持有這家生物技術公司的102,200股股票。截至最近提交給美國證券交易委員會的文件,復興技術公司擁有普羅吉治療公司約0.59%的股份,價值83,000美元。該公司3.50%的股份目前由機構投資者持有。
Protagenic Therapeutics Company Profile
普羅他尼治療公司簡介
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
前列基因治療公司是一家生物製藥公司,致力於發現和開發治療與壓力相關的神經精神和情緒障礙的療法。它的先導化合物是PT00114,這是Teneurin羧基末端相關肽的合成形式,Teneurin羧基末端相關肽是一種內源性大腦信號肽,可以抑制過度活躍的應激反應。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免費獲取StockNews.com關於前列腺素治療(PTIX)的研究報告
- 這三份報告將告訴我們許多關於當前經濟的情況。
- 下面的五個是不是打得太高了?
- 這就是現在對標準普爾500指數的預期
- 關於甲骨文的FQ1報告,你需要知道的兩件事
- 波動市場的三隻價值股
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅汀治療日報》的新聞和評級-在下面輸入您的電子郵件地址,即可通過MarketBeat.com的免費每日電子郵件時事通訊,收到對Protag Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧